Cequent
Marina Biotech announced last week that it has closed its Cambridge, Mass., operations and is consolidating all of its research and development activities at its Bothell, Wash. headquarters.
The move marks the company's foray into the ranks of clinical-stage drug developers and its first steps toward becoming a therapeutics marketer.
Some players in the field cautioned that the industry may be too focused on lipid delivery, potentially passing over other technologies that, while at an earlier stage of development, may ultimately be successful for certain indications.
Calando's management remains optimistic about deals in 2011. But some industry observers expect that it will take years of continued advancement in the RNAi field and a shift in its players' expectations before major deals are consummated.
"Clinical site approval at MGH marks the last regulatory requirement prior to moving our first drug candidate into human trials," Michael French, president and CEO of Marina, said in a statement.
Jul 22, 2010
Jul 15, 2010
Jun 24, 2010
Apr 15, 2010
Apr 8, 2010
Apr 1, 2010
Mar 11, 2010
Dec 31, 2009
Dec 10, 2009
Nov 19, 2009
Aug 20, 2009
Feb 12, 2009